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  Development	  of	  Peptide	  Cyclization	  Strategies	  for	  their	  Incorporations	  into	  
One-­‐Bead-­‐One	  Compound	  Peptide	  Libraries	  By:	  Lauren	  Elizabeth	  Blair	  Thesis	  Advisor:	  Professor	  Jianmin	  Gao	  Abstract:	  Cyclic	  peptides	  provide	  a	  privileged	  scaffold	  when	  optimizing	  interactions	  with	  various	  biological	  targets.	  Their	  rigidified	  structure	  decreases	  the	  entropic	  cost	  of	  binding	  by	  preorganizing	  residues	  in	  a	  fixed	  conformation,	  which	  may	  enhance	  binding	  affinity.	  These	  molecules	  occupy	  a	  larger	  chemical	  space	  than	  typical	  small	  molecule	  drugs	  and	  may	  provide	  good	  candidates	  for	  inhibiting	  protein-­‐protein	  interactions	  or	  being	  able	  to	  interact	  with	  previously	  undruggable	  targets.	  Given	  the	  benefits	  of	  these	  structures	  we	  aim	  to	  develop	  a	  one-­‐bead-­‐one-­‐compound	  peptide	  library	  for	  screening	  against	  relevant	  biological	  targets.	  Herein	  we	  describe	  several	  routes	  to	  achieving	  cyclic	  peptides	  through	  side	  chain	  interactions	  and	  head-­‐to	  tail	  amide	  bond	  linkages.	  Additional	  considerations	  for	  the	  development	  of	  the	  on	  resin	  library	  such	  as	  linker	  strategies	  and	  sequencing	  methods	  will	  be	  discussed.	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Chapter	  1:	  Introduction	  
1.1	  Potential	  of	  cyclic	  peptides	  	  	   Cyclic	  peptides	  can	  provide	  a	  rigidified	  structure	  that	  preorganizes	  residues	  in	  a	  beneficial	  manner	  to	  decrease	  the	  entropic	  cost	  for	  target	  binding.	  Often	  cyclization	  makes	  these	  peptides	  less	  susceptible	  to	  proteolytic	  degradation	  than	  their	  linear	  counterparts.	  	  As	  such	  privileged	  structures	  we	  find	  them	  to	  be	  an	  excellent	  candidate	  for	  binding	  membrane	  lipids1,	  disrupting	  protein-­‐protein	  interactions2,3	  and	  mimicking	  larger	  protein	  surfaces.	  	  Cyclic	  peptides	  occupy	  an	  area	  of	  chemical	  space	  that	  is	  inaccessible	  to	  small	  molecules	  and	  large	  biological	  polymers	  and	  are	  of	  particular	  interest	  to	  the	  scientific	  community.	  	  
1.2	  Methods	  of	  peptide	  cyclization	  through	  natural	  peptide	  functionalities	  
1.2.1	  Backbone	  cyclization	  	   One	  of	  the	  most	  commonly	  used	  methods	  for	  peptide	  cyclization	  is	  forming	  an	  amide	  linkage	  through	  the	  backbone	  amine	  and	  carboxy	  terminus	  of	  the	  peptide	  on	  resin.	  This	  method	  of	  cyclization	  relies	  on	  having	  an	  accessible	  N-­‐terminus	  and	  C-­‐terminus	  for	  cyclization	  to	  occur.	  In	  order	  to	  achieve	  this,	  there	  must	  be	  side	  chain	  immobilization	  of	  the	  peptide	  to	  the	  resin,	  requiring	  either	  the	  use	  of	  a	  glutamic	  acid	  or	  an	  aspartic	  acid	  on	  the	  Wang	  resin	  or	  the	  use	  of	  a	  glutamine	  or	  asparagine	  on	  the	  Rink	  Amide	  resin.	  This	  method	  of	  peptide	  cyclization	  was	  demonstrated	  within	  our	  lab	  with	  the	  synthesis	  of	  cLac,	  a	  13	  amino	  acid	  cyclic	  peptide.1	  cLac	  is	  a	  cyclic	  peptide	  that	  mimics	  the	  functional	  surface	  of	  a	  larger	  protein.	  Its	  protein	  mimic,	  Lactadherin,	  a	  47kDa	  protein	  selectively	  binds	  phosphatidyl	  serine.	  cLac	  can	  also	  bind	  PS	  through	  its	  rigidified	  cyclic	  peptide	  scaffold	  that	  displays	  the	  functional	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residues	  for	  PS	  binding.1	  One	  of	  the	  main	  limitations	  of	  this	  method	  is	  the	  reliance	  on	  the	  presence	  of	  glutamine,	  asparagine	  glutamate	  or	  aspartate	  residues	  in	  the	  peptide	  sequence.	  
	  
Figure	  1.	  cLac	  structure	  (adapted	  from	  [1])	  	   Backbone	  cyclization	  can	  also	  be	  achieved	  using	  the	  split-­‐intein	  circular	  ligation	  of	  peptides	  and	  proteins	  or	  SICLOPPS.4	  Through	  this	  methodology	  the	  desired	  cyclic	  peptide	  is	  expressed	  as	  a	  linear	  fusion	  protein	  with	  a	  split	  intein,	  which	  can	  then	  form	  the	  active	  intein	  to	  elicit	  the	  thioester	  intermediate	  formation.4	  This	  intermediate	  can	  then	  undergo	  rearrangement	  to	  form	  the	  final	  cyclic	  peptide	  with	  an	  amide	  linkage.4	  While	  this	  cyclization	  strategy	  affords	  a	  conformationally	  rigid	  cyclic	  peptide,	  the	  mechanism	  of	  SICLOPPS	  requires	  a	  cysteine	  within	  the	  sequence,	  a	  potential	  drawback	  if	  this	  residue	  should	  not	  be	  in	  the	  final	  product.	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1.2.2	  Disulfide	  bridges	  	   In	  addition	  to	  backbone	  cyclization,	  several	  other	  groups	  have	  opted	  to	  utilize	  the	  reactivity	  of	  side	  chains	  to	  cyclize	  peptides.	  One	  of	  the	  most	  commonly	  used	  side	  chain	  cyclization	  methods	  is	  the	  formation	  of	  a	  disulfide	  bond	  between	  two	  cysteine	  residues.	  The	  Nilsson	  group	  used	  the	  disulfide	  strategy	  to	  cyclize	  the	  short	  peptide	  Ac-­‐C(FKFE)2CG-­‐NH2	  to	  lock	  the	  conformation	  of	  the	  peptide.5	  This	  disulfide	  linkage	  provided	  a	  switch	  that	  could	  be	  controlled	  through	  reduction	  to	  create	  hydrogels	  of	  linear	  beta	  sheets.5	  The	  Schultz	  group	  used	  this	  disulfide	  formation	  to	  cyclize	  and	  staple	  short	  alpha	  helical	  peptides	  using	  an	  unnatural	  cysteine	  homolog.6	  This	  case	  presents	  an	  example	  of	  peptide	  cyclization	  to	  enhance	  the	  secondary	  structure	  of	  the	  peptide6,	  in	  contrast	  to	  the	  work	  by	  Nilsson	  and	  coworkers	  that	  seeks	  to	  prevent	  beta	  strand	  and	  hydrogel	  formation.5	  
1.2.3	  Lysine	  reactivity	  for	  peptide	  cyclization	  	   Other	  methods	  of	  peptide	  cyclization	  take	  advantage	  of	  the	  reactivity	  of	  lysine	  side	  chains.	  Short	  peptides	  of	  varying	  sequence	  have	  shown	  to	  be	  tolerated	  in	  the	  transglutaminase	  mediated	  cyclization	  of	  glutamic	  acid	  and	  lysine.7	  Lysine	  can	  also	  react	  with	  organic	  linkers	  to	  form	  cyclic	  peptides	  through	  bridging	  by	  iodoacetic	  anhydride8	  or	  disuccinimidyl	  glutarate.9,10	  
1.3	  Unnatural	  peptide	  cyclization	  strategies	  	   While	  many	  groups	  have	  taken	  advantage	  of	  these	  cyclization	  strategies	  of	  natural	  amino	  acids,	  still	  others	  have	  adopted	  unnatural	  amino	  acids	  to	  assist	  in	  the	  synthesis	  of	  cyclic	  peptides.	  Allyl	  protected	  homoserine,	  incorporated	  into	  short	  peptide	  sequences,	  undergoes	  intramolecular	  ring	  closing	  metathesis	  to	  afford	  cyclic	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peptide	  targets.11	  The	  Fasan	  group	  has	  introduced	  a	  mixed	  approach	  to	  peptide	  cyclization	  by	  performing	  ribosomal	  synthesis	  of	  macrocyclic	  peptides	  with	  unnatural	  amino	  acids	  containing	  aminothiol	  moieties.	  The	  unnatural	  linkages	  make	  the	  cyclic	  peptides	  highly	  stable,	  yet	  amendable	  to	  biological	  peptide	  synthesis	  methods.12	  	   Organic	  crosslinkers	  have	  also	  shown	  increasing	  prevalence	  in	  cyclic	  and	  bicyclic	  peptide	  chemistry.	  The	  reactivity	  of	  cysteine	  makes	  it	  suitable	  for	  reacting	  with	  organic	  crosslinkers.13	  The	  resulting	  thioether	  linkages	  are	  not	  susceptible	  to	  reductive	  conditions,	  making	  them	  more	  stable	  than	  their	  disulfide	  counterparts.13	  Dichloroacetone	  can	  also	  react	  with	  two	  cysteine	  residues	  to	  cyclize	  peptides,	  providing	  a	  ketone	  handle	  for	  oxime	  ligation	  with	  various	  labels.14	  Additionally,	  thioethers	  can	  be	  generated	  from	  disulfide	  bridged	  cyclic	  peptides	  through	  desulfurization	  using	  base	  or	  through	  beta	  elimination	  followed	  by	  a	  Michael	  addition.19	  	   A	  combination	  of	  unnatural	  amino	  acids	  and	  organic	  crosslinkers	  can	  afford	  bio	  orthogonal	  peptide	  cyclization.	  The	  Horne	  group	  has	  demonstrated	  that	  unnatural	  amino	  acids	  presenting	  oxyamine	  moieties	  readily	  react	  with	  dialdehyde	  linkers	  of	  varying	  orientation.15	  The	  Cochran	  group	  also	  made	  use	  of	  this	  methodology	  with	  (aminooxyacetyl)-­‐L-­‐2,3-­‐diaminopropionic	  acid	  and	  an	  extended	  dialdehyde	  linker	  to	  link	  two	  knottin	  peptides	  together,	  showcasing	  the	  broad	  applicability	  of	  this	  chemistry.16	  This	  strategy	  has	  also	  been	  demonstrated	  to	  work	  intramolecularly	  to	  crosslink	  aldehyde	  and	  oxyamine	  side	  chains	  with	  the	  goal	  of	  enabling	  dynamic	  covalent	  exchange	  in	  water	  .17,18,	  20	  The	  applicability	  of	  this	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chemistry	  to	  aqueous	  solutions	  suggests	  potential	  benefit	  over	  those	  requiring	  organic	  solvents	  or	  cofactors	  to	  assist	  in	  cyclization.18,20	  Through	  selection	  of	  the	  nucleophilic	  residue	  it	  is	  possible	  to	  tune	  the	  degree	  of	  peptide	  cyclization,	  which	  makes	  this	  chemistry	  and	  similar	  chemistries	  suitable	  for	  making	  reversibly	  cyclic	  peptides.	  
1.4	  Examples	  of	  natural	  multicyclic	  peptides	  	   Nature	  has	  many	  examples	  of	  rigid	  peptides	  such	  as	  the	  cysteine-­‐knot	  motif,	  a	  constrained	  peptide	  scaffold	  with	  head	  to	  tail	  cyclization	  bearing	  several	  disulfide	  bonds	  that	  are	  often	  interwoven	  throughout	  the	  peptide	  chain.21	  This	  class	  of	  peptides	  presents	  broad	  biological	  functions	  including	  antibiotic,	  anti-­‐HIV,	  and	  antitumor	  activities.21	  These	  peptides	  are	  achieved	  in	  nature	  through	  a	  macrolactam	  backbone	  cyclization	  in	  addition	  to	  multiple	  of	  disulfide	  bridges.21	  A	  structural	  class	  of	  knotted	  peptides	  is	  lantibiotics,	  antibiotic	  peptides	  containing	  lanthionine.22,23	  Lantibiotics	  contain	  a	  thioether	  bridge	  formed	  via	  post-­‐translational	  modification.23	  In	  these	  peptides,	  either	  serine	  or	  threonine	  dehydrate	  via	  the	  LanB	  enzyme	  to	  generate	  the	  corresponding	  α,β unsaturated	  amino	  acids,	  which	  then	  undergo	  cyclization	  via	  the	  enzyme	  LanC.23	  	  Their	  extreme	  structural	  rigidity	  and	  diverse	  biological	  functions	  have	  drawn	  attention	  to	  this	  class	  of	  molecules	  in	  recent	  years.	  Such	  complex	  bridging	  patterns	  have	  encouraged	  chemists	  to	  seek	  multicyclic	  peptides	  via	  various	  routes	  that	  will	  be	  discussed	  below.	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1.5	  Bicyclic	  peptide	  strategies	  	   Structurally	  rigidified	  bicyclic	  peptides	  have	  been	  sought	  after	  by	  many	  groups	  in	  hopes	  of	  inhibiting	  protein-­‐protein	  interaction24	  or	  probing	  various	  protein	  targets.25	  The	  Heinis	  group	  thought	  to	  incorporate	  an	  unnatural	  amino	  acids	  L-­‐4,5-­‐dithiolnorvaline	  into	  peptides	  in	  order	  to	  promote	  disulfide	  bridging	  to	  free	  cysteines.24	  This	  strategy	  creates	  bicyclic	  peptides	  via	  oxidation	  of	  the	  unnatural	  amino	  acid	  along	  with	  two	  cysteines.24	  The	  selected	  peptide	  sequences	  were	  found	  to	  mimic	  their	  natural	  cysteine	  knot	  models	  and	  the	  optimized	  bicyclic	  ligand	  was	  found	  to	  inhibit	  the	  target	  protein	  with	  40-­‐fold	  greater	  efficiency	  than	  that	  of	  the	  original	  peptide.24	  While	  the	  work	  of	  the	  Heinis	  group	  provides	  a	  way	  to	  prepare	  bicyclic	  peptides	  on	  solid	  support24,	  the	  Fasan	  group	  reported	  the	  preparation	  of	  bicyclic	  peptides	  through	  recombinant	  methods.25	  Their	  work	  featured	  the	  split	  intein-­‐catalyzed	  head-­‐to-­‐tail	  cyclization,	  described	  previously	  as	  the	  SICLOPPS	  method,	  to	  form	  a	  mono	  cyclic	  peptide	  which	  they	  then	  converted	  to	  a	  bicyclic	  peptide	  through	  inter-­‐side-­‐chain	  crosslinking	  of	  an	  unnatural	  O2beY	  amino	  acid	  and	  a	  cysteine.25	  This	  methodology	  allowed	  them	  to	  access	  a	  variety	  of	  bicyclic	  peptides,	  and	  proved	  useful	  in	  optimizing	  peptides	  for	  protein	  binding.25	  	   Side	  chain	  conjugation	  has	  proven	  to	  be	  an	  effective	  method	  for	  several	  groups21-­‐25,	  but	  the	  rigid	  peptide	  scaffolds	  can	  also	  be	  made	  via	  intermolecular	  reactions.26,27	  The	  Heinis	  group	  focused	  much	  of	  their	  efforts	  toward	  achieving	  bicyclic	  peptides	  with	  cysteine-­‐reactive	  small	  molecules	  such	  as	  tris(bromomethyl)benzene26-­‐28,	  1,3,5-­‐triacryloyl-­‐1,3,5-­‐triazinane	  and	  N,N’,N”-­‐(benzene-­‐1,3,5-­‐triyl)-­‐tris(2-­‐bromoacetamide)	  (Figure	  2).26	  These	  small	  molecule	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crosslinkers	  were	  beneficial	  to	  forming	  structurally	  rigid	  peptides	  first	  by	  bicyclizing	  the	  peptides	  through	  covalent	  reactions	  with	  cysteines	  and	  then	  by	  forming	  noncovalent	  interactions	  with	  other	  amino	  acid	  side	  chains.26	  	  	  This	  bicyclization	  strategy	  was	  found	  to	  be	  applicable	  to	  phage-­‐displayed	  libraries	  as	  well	  as	  solid	  phase	  peptide	  synthesis.26	  The	  Pei	  laboratory	  used	  a	  similar	  approach	  to	  synthesize	  bicyclic	  peptides	  on	  resin	  using	  trimesic	  acid	  that	  conjugates	  with	  the	  N-­‐terminus	  and	  two	  2,3-­‐diaminopropionic	  acid	  residues	  in	  the	  peptide	  sequence.29	  
	  
Figure	  2.	  Organic	  scaffolds	  for	  peptide	  bicyclization	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with	  small	  alpha	  nucleophiles	  and	  biological	  amines30,	  we	  sought	  to	  broaden	  the	  scope	  of	  this	  chemistry	  toward	  its	  implementation	  into	  peptide	  cyclization.30,31	  Importantly,	  the	  imino	  boronate-­‐based	  peptide	  cyclization	  can	  be	  reversible	  by	  competing	  away	  the	  iminoboronate	  through	  the	  addition	  of	  a	  stronger	  alpha	  nucleophile.	  Additionally	  this	  methodology	  provides	  the	  ability	  to	  tune	  the	  degree	  of	  interaction	  by	  adjusting	  the	  pH	  of	  the	  solution,	  which	  makes	  the	  iminoboronate	  based	  cyclization	  reversible.	  This	  is	  highly	  desirable	  for	  developing	  peptide	  cyclization	  chemistries	  that	  would	  be	  applicable	  to	  both	  screening	  and	  sequencing	  protocols.	  
	  
Figure	  3.	  Iminoboronate	  formation	  with	  various	  nucleophiles	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a	  randomized,	  unbiased	  peptide	  library	  may	  offer	  the	  best	  array	  of	  molecules	  when	  screening	  against	  a	  target	  of	  interest.	  Three	  major	  classes	  of	  library	  development	  exist	  in	  the	  peptide	  field.	  mRNA	  display	  utilizing	  the	  PURE	  system	  is	  a	  useful	  tool	  for	  library	  construction	  and	  screening.33	  This	  method	  provides	  a	  means	  for	  covalently	  linking	  the	  genetic	  information	  that	  encodes	  peptides	  to	  the	  peptides	  themselves	  through	  a	  Puromycin	  linker.33	  This	  approach	  provides	  a	  diversity	  of	  ~1012	  accessible	  compounds	  for	  screening.33	  Once	  compounds	  have	  been	  identified	  as	  “hits”	  the	  peptide-­‐mRNA	  complexes	  can	  undergo	  PCR	  amplification	  and	  DNA	  sequencing	  to	  reveal	  the	  sequence	  of	  the	  peptide	  binder.33	  	  Another	  biological	  method	  of	  library	  synthesis	  involves	  the	  use	  of	  phage	  and	  their	  ease	  of	  their	  genome	  manipulation	  to	  express	  a	  variety	  of	  short	  peptide	  variants	  onto	  their	  coat	  proteins.34	  These	  libraries	  have	  a	  diversity	  of	  ~108	  and	  can	  be	  useful	  for	  finding	  low	  micromolar	  and	  nanomolar	  peptide	  binding	  sequences	  through	  multiple	  rounds	  of	  panning.34	  A	  more	  chemical	  approach	  to	  peptide	  libraries	  involves	  the	  use	  of	  one-­‐bead-­‐one-­‐compound	  (OBOC)	  or	  one-­‐bead-­‐two-­‐compound	  (OBTC)	  peptide	  libraries.35.36	  Previous	  work	  in	  the	  Pei	  laboratory	  has	  demonstrated	  such	  methods	  are	  easily	  accessible	  and	  prove	  to	  be	  good	  tools	  for	  finding	  inhibitors	  of	  protein-­‐protein	  interactions.	  Variations	  in	  peptide	  sequence	  can	  be	  achieved	  through	  split-­‐pool	  synthesis	  method	  where	  different	  amino	  acids	  are	  coupled	  to	  portions	  of	  resin.	  The	  resin	  portions	  are	  then	  mixed	  together	  and	  re-­‐split	  into	  new	  portions	  to	  couple	  with	  
	   10	  
new	  amino	  acids	  (Figure	  4).	  This	  strategy	  creates	  a	  randomized	  peptide	  library	  where	  each	  bead	  presents	  only	  one	  congruent	  sequence	  for	  screening.	  
	  
Figure	  4.	  Split-­‐pool	  synthesis	  method	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screen	  for	  sequences	  that	  selectively	  bind	  targets	  of	  biological	  relevance	  such	  as	  the	  membrane	  lipid	  phosphatidylserine.	  We	  then	  propose	  to	  linearize	  these	  cyclic	  peptides	  for	  sequencing.	  
Chapter	  2:	  Experiments	  and	  Results	  
2.1	  On	  resin	  head	  to	  tail	  cyclization	  	  	   Initial	  attempts	  at	  the	  development	  of	  an	  on	  resin	  cyclic	  peptide	  library	  focused	  on	  identifying	  an	  adequate	  method	  for	  peptide	  cyclization.	  We	  sought	  to	  utilize	  the	  previously	  developed	  cLac	  peptide	  shown	  in	  Figure	  5	  as	  a	  model	  sequence	  for	  optimization	  of	  head	  to	  tail	  of	  cyclization.	  Screening	  of	  coupling	  reagents	  proved	  PyBOP	  to	  have	  more	  synthetic	  utility	  than	  HATU,	  and	  HBTU.	  This	  selected	  coupling	  agent	  was	  taken	  on	  for	  further	  screening	  of	  	  reaction	  conditions	  such	  as	  solvent	  and	  temperature	  effects	  on	  cyclization	  efficiency.	  Data	  obtained	  from	  these	  screens	  showed	  that	  up	  to	  79%	  conversion	  from	  linear	  to	  cyclic	  peptide	  could	  be	  obtained	  with	  heating	  to	  82°C	  for	  4	  hours	  in	  N,	  N’-­‐Dimethylformamide	  (DMF)	  with	  only	  15%	  of	  peptide	  forming	  the	  undesired	  dimers.	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   After	  further	  consideration	  of	  this	  cyclization	  strategy,	  we	  concluded	  that	  head	  to	  tail	  cyclization,	  while	  efficient	  enough,	  would	  not	  be	  a	  good	  approach	  for	  the	  development	  of	  a	  one-­‐bead-­‐one-­‐compound	  (OBOC)	  library	  due	  to	  the	  difficulty	  of	  sequencing	  backbone	  cyclized	  peptides.	  Edman	  degradation	  would	  not	  be	  accessible	  due	  to	  the	  lack	  of	  a	  free	  N-­‐terminus	  and	  mass	  spectrometry	  would	  produce	  random	  peptide	  fragments	  that	  would	  be	  difficult	  to	  piece	  back	  together.	  	  Due	  to	  this	  limitation,	  other	  approaches	  to	  peptide	  cyclization	  and	  bicyclization	  were	  examined	  through	  side	  chain	  crosslinking.	  
2.2	  Bicyclization	  through	  organic	  crosslinkers	  Previous	  reports	  from	  the	  Heinis	  group	  described	  bicyclic	  peptide	  formation	  on	  phage	  for	  panning	  against	  various	  targets37.	  We	  believe	  our	  on	  resin	  library	  would	  behave	  much	  like	  the	  phage	  in	  solution	  so	  we	  sought	  to	  find	  optimal	  conditions	  to	  synthesize	  bicyclic	  peptides	  on	  resin	  utilizing	  the	  organic	  crosslinker	  tris-­‐bromomethyl	  benzene	  (TBMB)	  and	  a	  reported	  sequence	  H2N-­‐ACVSWHGGCHPQGDICC-­‐OH	  (Scheme	  1).37	  Solution	  phase	  cyclization	  of	  the	  above	  sequence	  with	  TBMB	  was	  achieved	  after	  incubating	  for	  1	  hour	  at	  30°C.	  The	  reaction	  was	  conducted	  in	  an	  ammonium	  carbonate	  buffer	  to	  ensure	  free	  thiolates	  for	  reactivity,	  and	  in	  the	  presence	  of	  acetonitrile	  to	  assist	  in	  TBMB	  solubility.	  	  With	  the	  success	  of	  solution	  phase	  cyclization,	  the	  reaction	  was	  further	  optimized	  to	  create	  bicyclic	  peptides	  on	  resin.	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Scheme	  1.	  Peptide	  bicyclization	  through	  tris-­‐bromomethylbenzene	  	  The	  solid	  phase	  peptide	  synthesis	  of	  the	  aforementioned	  sequence	  incorporated	  an	  orthogonal	  cysteine	  protecting	  group,	  (4-­‐methoxyphenyl)diphenylmethyl.	  This	  provided	  a	  means	  to	  selectively	  generate	  free	  thiols	  for	  reacting	  with	  TBMB.	  The	  Ellman	  test	  identified	  a	  small	  percentage	  of	  free	  thiols	  on	  resin,	  and	  when	  these	  peptides	  were	  further	  screened	  for	  reactivity	  with	  TBMB,	  only	  minimal	  peptide	  bicyclization	  was	  achieved	  even	  with	  optimized	  conditions	  (1.5	  equivalents	  of	  TBMB,	  3	  equivalents	  of	  TCEP	  in	  the	  presence	  of	  2	  equivalents	  of	  diisopropylethylamine	  (DIPEA)	  for	  two	  hours	  at	  30°C).	  	  
	  
2.3	  Synthesis	  of	  unnatural	  amino	  acid	  AB1	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iminoboronate	  that	  can	  easily	  be	  competed	  away	  by	  small	  molecule	  addition	  or	  pH	  tuning,	  thus	  allowing	  facile	  control	  peptide	  cyclization.	  	   Synthetic	  approaches	  to	  the	  unnatural	  amino	  acid	  AB1	  had	  been	  reported	  by	  our	  laboratory	  and	  are	  described	  below	  in	  Scheme	  2.	  The	  route	  to	  AB1	  begins	  with	  a	  simple	  Boc	  protection	  that	  affords	  intermediate	  2	  in	  high	  yields	  and	  purities.	  The	  boc	  protected	  intermediate	  2	  was	  reduced	  using	  tri-­‐n-­‐butylphosphine.	  While	  this	  reaction	  could	  be	  done	  on	  large	  scale,	  several	  problems	  arose	  with	  this	  step.	  The	  first	  issue	  came	  from	  purification	  of	  the	  free	  thiol.	  Column	  purification	  with	  air	  caused	  the	  reduced	  cysteine	  to	  re-­‐oxidize	  on	  column	  and	  compromised	  the	  product	  purity.	  Furthermore,	  an	  unidentifiable	  side	  product	  co-­‐eluted	  frequently	  with	  the	  desired	  product,	  affecting	  product	  purity	  and	  potentially	  affecting	  the	  subsequent	  reactions.	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   The	  UV	  initiated	  thiol-­‐ene	  reaction	  appeared	  sensitive	  to	  the	  purity	  of	  the	  cysteine	  starting	  material.	  The	  residual	  unidentified	  compound	  appeared	  to	  compromise	  the	  reaction.	  The	  percentage	  of	  cystine	  increased	  over	  the	  course	  of	  the	  reaction,	  further	  reducing	  the	  yield.	  	  	   Miyaura	  borylation	  of	  intermediate	  6	  also	  gave	  lower	  than	  reported	  yields	  in	  my	  hands	  with	  typical	  yields	  close	  to	  30%.	  This	  appeared	  to	  be	  due	  to	  sensitivity	  to	  moisture,	  which	  we	  tried	  to	  overcome	  by	  utilizing	  molecular	  sieves	  and	  purging	  of	  the	  reaction	  with	  argon.	  Additionally,	  this	  reaction	  appeared	  to	  be	  extremely	  temperature	  sensitive.	  Ultimately	  this	  reaction	  was	  executed	  so	  that	  enough	  material	  could	  be	  obtained	  for	  peptide	  synthesis.	  
2.4	  Incorporation	  of	  AB1	  into	  model	  peptide	  sequences	  	   Once	  AB1	  had	  been	  synthesized	  in	  sufficient	  quantities,	  its	  potential	  to	  induce	  peptide	  cyclization	  was	  explored	  using	  model	  peptide	  sequences.	  We	  first	  incorporated	  these	  unnatural	  amino	  acids	  into	  short	  peptide	  sequences	  that	  included	  either	  a	  Dap(alphahydroxy	  amino)	  residue,	  abbreviated	  as	  Dap(aoa),	  in	  sequences	  LB02-­‐132	  and	  LB02-­‐131	  or	  a	  lysine	  residue	  as	  a	  nucleophile	  in	  sequences	  SD01-­‐93	  and	  SD01-­‐94	  (Figure	  6).	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(Figure	  7).	  Based	  on	  the	  data	  obtained,	  a	  significant	  shift	  in	  the	  absorption	  maximum	  was	  observed	  for	  lysine	  and	  2-­‐APBA,	  while	  a	  less	  obvious	  shift	  was	  observed	  for	  the	  conjugation	  of	  2-­‐APBA	  with	  AOHA.	  These	  initial	  data	  provided	  a	  basis	  for	  our	  assessment	  of	  the	  intramolecular	  iminoboronate	  formation	  of	  the	  model	  peptides.	  Peptides	  containing	  Dap(aoa)	  residues	  appear	  to	  have	  a	  slight	  shift	  in	  the	  maximum	  absorption	  wavelengths	  when	  AB1	  is	  2	  residues	  away	  from	  Dap(aoa)	  suggesting	  intramolecular	  iminoboronate	  formation	  (Figure	  8).This	  is	  comparable	  to	  the	  UV	  data	  of	  the	  small	  molecule	  control	  experiments	  presented	  in	  Figure	  7,	  where	  iminoboronate	  formation	  is	  observed	  as	  a	  shift	  toward	  270nm	  from	  the	  free	  2-­‐APBA	  absorption	  maximum	  of	  250nm.	  This	  favored	  interaction	  of	  the	  i+2	  versus	  the	  i+3	  position	  may	  be	  due	  to	  orientation	  of	  the	  residues	  in	  space	  rather	  than	  the	  distance	  between	  the	  2-­‐APBA	  head	  group	  and	  the	  nucleophilic	  residue.	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molecules	  may	  have	  strong	  interactions	  with	  AB1with	  Kd’s	  of	  14μM,	  the	  conjugation	  of	  hydrazine	  functionalized	  molecules	  was	  much	  stronger	  with	  Kd’s	  of	  70nM.	  Based	  on	  these	  data	  we	  synthesized	  short	  peptide	  H2N-­‐AB1GGDap(aoa)W-­‐OH.	  To	  our	  delight	  we	  observed	  the	  expected	  concentration	  dependence	  for	  the	  external	  small	  molecule	  competitors	  the	  intramolecular	  iminoboronate.	  6-­‐aminooxyhexanoic	  acid	  appeared	  to	  compete	  away	  40%	  of	  the	  peptide’s	  intramolecular	  iminoboronates	  with	  concentrations	  greater	  than	  100	  μM	  (Figure	  9).	  This	  plateau	  is	  due	  to	  the	  high	  reversibility	  of	  this	  conjugation,	  allowing	  a	  rapid	  exchange	  between	  the	  intramolecular	  iminoboronate	  and	  the	  intermolecular	  iminoboronate.	  We	  sought	  to	  improve	  upon	  this	  competition	  with	  a	  stronger	  nucleophile	  4-­‐hydrazinobenzoic	  acid.	  	  As	  we	  predicted,	  4-­‐hydrazinobenzoic	  acid,	  at	  greater	  than	  1.5	  equivalents,	  allowed	  us	  to	  linearize	  the	  peptide	  100%	  (Figure	  10).	  The	  ability	  to	  tune	  the	  degree	  of	  peptide	  cyclization	  through	  iminoboronate	  chemistry	  could	  be	  useful	  for	  controlling	  peptide	  structure	  and	  activity.	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Figure	  10.	  Interaction	  of	  4-­‐hydrazinobenzoic	  acid	  with	  model	  peptide	  H2N-­‐AB1GGDap(aoa)W-­‐OH.	  Peptide	  concentration	  was	  held	  constant	  at	  50μM.	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deprotection	  of	  the	  amine	  with	  80%	  trifluoroacetic	  acid	  in	  dichloromethane	  affords	  intermediate	  5,	  which	  can	  then	  be	  coupled	  to	  free	  glutamate	  and	  aspartate	  residues	  through	  amide	  bond	  formation	  (Scheme	  4).	  Additionally,	  the	  free	  amine	  can	  be	  coupled	  with	  iodoacetamide	  derivatives	  to	  provide	  a	  reactive	  handle	  to	  couple	  free	  cysteines.	  	  
	  
Scheme	  4.	  Peptide	  modification	  with	  LB1	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utilization	  of	  a	  known	  23	  amino	  acid	  peptide,	  Magainin	  2	  (Figure11)42.	  This	  peptide	  presents	  an	  alpha	  helical	  structure	  with	  antibiotic	  activities42.	  Intramolecular	  peptide	  cyclization	  through	  iminoboronate	  chemistry	  could	  prohibit	  helix	  formation,	  while	  cleavage	  of	  the	  intramolecular	  iminoboronate	  would	  regenerate	  the	  helical	  and	  active	  peptide.	  
	  
Figure	  11.	  Helical	  representation	  of	  Magainin	  2	  (adapted	  from	  [42])	  	   	   Our	  design	  of	  this	  model	  peptide	  included	  a	  mutation	  of	  glycine	  3	  to	  a	  glutamate	  utilizing	  an	  allyl	  protected	  glutamate	  residue	  for	  orthogonal	  deprotection	  prior	  to	  LB1coupling.	  We	  also	  mutated	  the	  C-­‐terminal	  serine	  to	  a	  Dap(aoa)	  residue	  to	  install	  an	  internal	  alpha	  nucleophile	  (Scheme	  5).	  Our	  hypothesis	  for	  this	  design	  proposed	  that	  the	  2-­‐APBA	  moiety	  and	  alpha	  nucleophile	  in	  the	  same	  peptide	  would	  allow	  us	  to	  form	  intramolecular	  iminoboronates	  and	  cyclize	  the	  peptide.	  We	  further	  postulated	  that	  this	  cyclization	  would	  disrupt	  the	  alpha	  helical	  structure	  of	  the	  peptide,	  which	  could	  then	  be	  recovered	  by	  competition	  with	  other	  alpha	  nucleophiles	  such	  as	  4-­‐hydrazinobenzoic	  acid	  or	  6-­‐aminooxyhexanoic	  acid	  as	  previously	  shown	  with	  smaller	  peptide	  models	  (Figures	  9	  &	  10).	  
	   26	  
	  
	  








































































































































































	   27	  
	  










Wild	  Type	  vs	  2-­‐APBA	  Mutant	  
10mM	  SDS	  WT	  10mM	  SDS	  Mutant	  30mM	  SDS	  WT	  30mM	  SDS	  Mutant	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Figure	  13.	  Changes	  in	  alpha	  helicity	  of	  Mag2-­‐LB1	  through	  conjugation	  with	  HBA	  in	  the	  presence	  of	  50mM	  SDS	  micelles	  










Mutant	  with	  50mM	  SDS	  and	  HBA	  
300uM	  HBA	  600uM	  HBA	  900uM	  HBA	  0uM	  HBA	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find	  a	  resin	  that	  would	  perform	  in	  aqueous	  environments.	  To	  circumvent	  this	  issue,	  we	  chose	  to	  incorporate	  the	  TentaGel-­‐S-­‐NH2	  resin.	  This	  resin	  has	  a	  polystyrene	  core	  with	  a	  polyethyleneglycol	  shell	  to	  aid	  in	  interactions	  with	  aqueous	  phases	  for	  screening	  of	  libraries.	  It	  is	  functionalized	  with	  an	  amine	  handle	  and	  has	  a	  low	  loading	  (0.26mmol/g)	  to	  allow	  displayed	  peptides	  to	  interact	  with	  the	  target	  of	  interest	  rather	  than	  other	  peptides	  on	  resin.	  Literature	  has	  shown	  that	  installing	  a	  C-­‐terminal	  methionine	  can	  provide	  a	  means	  for	  peptide	  cleavage	  from	  the	  resin	  that	  is	  compatible	  with	  side	  chain	  protection	  and	  peptide	  sequencing.	  Unfortunately,	  treatment	  with	  cyanogen	  bromide	  not	  only	  cleaved	  the	  peptides	  from	  resin,	  but	  severely	  degraded	  the	  resin	  contaminating	  the	  obtained	  mass	  spectra	  with	  PEG	  units.	  While	  bulk	  cleavage	  of	  the	  resin	  still	  resulted	  in	  the	  observation	  of	  the	  desired	  peptide	  mass,	  single	  bead	  cleavage	  resulted	  in	  only	  PEG	  units	  in	  the	  mass	  spectra	  as	  their	  concentration	  significantly	  suppressed	  the	  signal	  of	  the	  desired	  peptide	  mass.	  It	  was	  clear	  that	  the	  harsh	  cyanogen	  bromide	  treatment	  was	  not	  optimal	  so	  we	  chose	  to	  look	  into	  more	  benign	  approaches	  to	  peptide	  cleavage.	  One	  such	  route	  was	  the	  incorporation	  of	  photo	  labile	  linkers	  as	  shown	  in	  Figure	  14.	  To	  determine	  the	  efficiencies	  and	  the	  kinetics	  of	  the	  photo	  cleavage	  of	  these	  linkers,	  short	  model	  peptide	  sequences	  were	  synthesized	  on	  the	  TentaGel	  resin.	  By	  installing	  a	  C-­‐terminal	  methionine	  residue	  alongside	  the	  photo	  labile	  linkers,	  we	  had	  a	  positive	  control	  for	  peptide	  cleavage.	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Figure	  15.	  	  Photo	  cleavage	  over	  time	  of	  model	  peptide	  with	  ANP	  linker	  under	  4W	  UV	  irradiation	  	   Knowing	  the	  low	  photo	  cleavage	  is	  not	  due	  to	  slow	  kinetics,	  we	  attempted	  to	  utilize	  more	  powerful	  light	  sources.	  Specifically,	  both	  of	  the	  model	  peptides	  in	  Figure	  13	  were	  subjected	  to	  a	  160W	  365nm	  UV	  lamp.	  To	  our	  delight,	  we	  observed	  98%	  photo	  cleavage	  from	  the	  resin	  bearing	  the	  Linker	  2	  and	  49%	  photo	  cleavage	  from	  the	  sequence	  incorporating	  the	  ANP	  linker.	  With	  this	  information	  we	  believe	  we	  will	  be	  able	  to	  incorporate	  these	  linkers	  into	  our	  OBOC	  library	  to	  allow	  efficient	  release	  of	  peptides	  for	  sequencing..	  
2.8	  Partial	  Edman	  Degradation	  Optimization	  Since	  finding	  the	  optimal	  resin	  and	  linker	  for	  our	  library	  development,	  we	  proceeded	  to	  work	  on	  development	  of	  library	  sequencing	  strategies.	  One	  commonly	  used	  method	  for	  sequencing	  is	  Partial	  Edman	  degradation,	  which	  uses	  phenylisocyante	  (PIC)	  and	  phenylisothiocyanate	  (PITC)	  to	  generate	  capped	  and	  cleaved	  peptide	  fragments	  respectively.	  These	  capped	  and	  cleaved	  products	  generate	  a	  peptide	  ladder	  over	  time	  that	  can	  be	  decoded	  to	  reveal	  the	  peptide	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sequence.	  As	  we	  began	  to	  explore	  this	  route	  to	  sequencing,	  we	  observed	  3	  distinct	  products	  from	  one	  round	  of	  degradation:	  the	  original	  peptide	  sequence,	  the	  PIC	  capped	  peptide	  and	  the	  N-­‐terminal	  truncated	  product.	  These	  findings	  suggest	  incomplete	  capping	  of	  the	  N-­‐terminus	  of	  the	  peptide.	  Upon	  further	  consideration,	  we	  reasoned	  that	  the	  incomplete	  capping	  of	  the	  original	  peptide	  should	  provide	  one	  of	  the	  rungs	  on	  our	  peptide	  sequencing	  ladder	  and	  could	  eliminate	  our	  need	  for	  a	  capping	  agent.	  We	  tested	  this	  hypothesis	  with	  a	  model	  peptide	  H2N-­‐DISFRW-­‐ANP-­‐MGG-­‐TentaGel	  Resin.	  The	  sequence	  was	  subjected	  to	  30-­‐minute	  incubation	  with	  phenylisothiocyanate,	  extensive	  washing	  and	  a	  10-­‐minute	  incubation	  with	  trifluoroacetic	  acid	  to	  cleave	  the	  N-­‐terminal	  residue.	  After	  one	  round	  of	  these	  conditions	  approximately	  80%	  of	  the	  peptide	  had	  degraded	  to	  produce	  the	  cycle	  1	  product	  with	  the	  deletion	  of	  the	  N-­‐terminal	  aspartate	  residue	  (Figure	  16).	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Remarkably,	  we	  observed	  all	  3	  deletion	  products	  and	  the	  original	  peptide	  sequence	  (Figure	  17).	  
	  
Figure	  17.	  Analysis	  of	  the	  peptide	  H2N-­‐DISFRW-­‐ANP-­‐MGG-­‐TentaGel	  Resin	  after	  3	  rounds	  of	  Partial	  Edman	  Degradation	  
2.9	  Mass	  Spectrometry	  Method	  Optimization	  
	   While	  the	  optimized	  Edman	  Degradation	  could	  potentially	  be	  a	  viable	  route	  for	  library	  sequencing,	  a	  serendipitous	  finding	  was	  uncovered	  that	  may	  make	  sequencing	  easier.	  It	  appeared	  that	  further	  examination	  of	  the	  mass	  spectra	  of	  the	  individual	  peaks	  showed	  a	  clear	  and	  obvious	  pattern	  of	  y	  ions	  (Figure	  18).	  This	  finding	  encouraged	  us	  to	  look	  further	  into	  optimizing	  LC-­‐MS	  methods	  to	  enhance	  the	  presence	  of	  these	  for	  peptide	  sequencing.	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   To	  improve	  sensitivity	  to	  detect	  low	  quantities	  of	  material	  we	  tested	  different	  parameters	  within	  our	  mass	  spectrometry	  method.	  The	  default	  capillary	  voltage	  setting	  is	  4000V,	  which	  is	  sufficient	  for	  most	  peptide	  samples.	  By	  increasing	  this	  voltage	  to	  higher	  values,	  there	  is	  a	  stronger	  attraction	  between	  the	  ions	  and	  the	  capillary,	  pulling	  the	  sample	  ions	  in	  with	  greater	  force	  and	  increasing	  the	  amount	  of	  sample	  that	  enters	  the	  mass	  spectrometer.	  Through	  100V	  incremental	  testing,	  we	  found	  4500V	  to	  be	  the	  optimal	  voltage	  for	  detecting	  small	  peptide	  samples	  and	  producing	  enhanced	  signals.	  	   The	  skimmer	  voltage	  was	  also	  a	  parameter	  we	  improved	  upon	  from	  the	  default	  setting	  of	  75V.	  Increasing	  the	  voltage	  of	  the	  skimmer	  produces	  greater	  force	  to	  send	  the	  sample	  ions	  up	  the	  time	  of	  flight	  (TOF)	  tube.	  Increasing	  this	  voltage	  increased	  the	  amount	  of	  ions	  that	  reach	  the	  detector,	  thus	  increasing	  the	  observed	  signal	  of	  the	  sample.	  After	  careful	  screening	  it	  was	  observed	  that	  115V	  produced	  the	  optimal	  signal.	  	   Increased	  signal	  results	  from	  increased	  amount	  of	  ions	  that	  reach	  the	  detector	  and	  further	  understanding	  the	  various	  parameters	  that	  can	  create	  more	  ions	  led	  us	  to	  investigating	  the	  drying	  gas	  temperature	  and	  flow	  rate.	  By	  increasing	  the	  temperature	  of	  the	  drying	  gas	  from	  300°C	  to	  350°C	  we	  were	  able	  to	  dry	  more	  of	  the	  sample	  droplets	  as	  they	  left	  the	  nebulizer,	  allowing	  more	  sample	  to	  enter	  the	  instrument.	  We	  did	  dot	  see	  improvement	  of	  detection	  with	  higher	  temperatures	  due	  to	  what	  we	  believe	  may	  have	  been	  thermal	  degradation.	  The	  flow	  rate	  of	  the	  drying	  gas	  temperature	  can	  also	  be	  varied,	  but	  we	  opted	  to	  disregard	  this	  parameter	  in	  our	  method	  optimization.	  With	  increased	  flow	  rate,	  the	  droplets	  will	  become	  drier,	  but	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may	  be	  pushed	  away	  from	  the	  capillary	  and	  will	  not	  enter	  the	  source.	  As	  the	  molecular	  weight	  of	  sample	  ions	  increases	  this	  becomes	  less	  of	  an	  issue,	  but	  with	  the	  small	  predicted	  molecular	  weights	  of	  our	  peptide	  library,	  we	  chose	  to	  leave	  the	  default	  flow	  rate	  of	  8L/minute.	  
	  
Figure	  19.	  Single	  bead	  peptide	  data	  of	  model	  sequence	  	   As	  shown	  in	  Figure	  19	  the	  peptide	  sample	  produced	  from	  photo	  irradiation	  of	  a	  single	  bead	  can	  be	  observed	  with	  the	  optimized	  parameters	  described	  above.	  Sequencing	  data	  are	  clearly	  observed	  in	  the	  mass	  spectrum	  of	  the	  sample	  in	  the	  form	  of	  the	  observed	  y	  ion	  pattern.	  
2.10	  Screening	  of	  peptide	  library	  
	   With	  sequencing	  methods	  and	  synthesis	  methods	  in	  place	  we	  sought	  to	  develop	  peptide	  libraries	  and	  screen	  them	  against	  our	  target	  of	  interest.	  Phosphatidylserine	  (PS)	  is	  a	  membrane	  lipid	  in	  mammalian	  cells	  that	  is	  expressed	  exclusively	  in	  the	  inner	  leaflet	  of	  healthy	  cells	  (Figure	  20).	  As	  the	  cell	  undergoes	  apoptosis	  phosphatidylserine	  is	  translocated	  to	  the	  outer	  leaflet	  and	  is	  exposed	  to	  the	  extracellular	  environment38-­‐40.	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Figure	  21.	  Peptide	  library	  design	  Preparation	  of	  liposomes	  is	  a	  well-­‐known	  laboratory	  technique	  in	  our	  lab	  so	  we	  sought	  to	  screen	  our	  preliminary	  library	  against	  fluorescently	  labeled	  liposomes.	  We	  synthesized	  a	  NBD	  labeled	  1-­‐palmitoyl-­‐2-­‐oleoyl-­‐sn-­‐glycero-­‐phosphatidyl	  ethanolamine	  using	  (POPE,	  Scheme	  6),	  which	  we	  incorporated	  as	  0.1%	  of	  the	  total	  lipid	  composition	  of	  our	  liposomes	  for	  screening.	  80%	  1-­‐palmitoyl-­‐2-­‐oleoyl-­‐sn-­‐glycero-­‐3-­‐phosphocholine	  (POPC)	  and	  20%	  1,2-­‐dioleoyl-­‐sn-­‐glycero-­‐3-­‐phospho-­‐L-­‐serine	  (DOPS)	  comprised	  the	  remainder	  of	  the	  liposome	  lipids.	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show	  varied	  fluorescence	  intensities,	  presumably	  due	  to	  varied	  degree	  of	  binding	  (Figure	  22).	  
	  
Figure	  22.	  Fluorescence	  images	  of	  peptides	  on	  resin	  upon	  binding	  to	  liposomes	  a)	  Beads	  alone	  bright	  field	  b)	  beads	  alone	  NBD	  fluorescence	  c)1mM	  liposome	  bright	  field	  d)	  1mM	  liposome	  NBD	  fluorescence	  e)1mM	  liposome,	  1x	  wash	  bright	  field	  f)	  1mM	  liposome	  NBD	  fluorescence	  g)	  1mM	  liposome,	  2x	  wash	  bright	  field	  h)	  1mM	  liposome	  NBD	  fluorescence	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Chapter	  3:	  Conclusions	  and	  Future	  Directions	  
	  We	  have	  demonstrated	  the	  accessibility	  of	  cyclic	  peptide	  scaffolds	  on	  resin	  through	  a	  variety	  of	  synthetic	  strategies.	  In	  addition	  to	  the	  head	  to	  tail	  cyclization,	  we	  have	  shown	  we	  can	  cyclize	  peptides	  through	  side	  chain	  crosslinking	  with	  organic	  crosslinkers	  or	  through	  incorporation	  of	  unnatural	  amino	  acids.	  Furthermore,	  we	  have	  shown	  the	  synthesis	  and	  utilization	  of	  reversibly	  cyclized	  of	  peptides	  through	  small	  molecule	  cleavage	  of	  the	  intramolecular	  iminoboronate	  linkage.	  This	  development	  will	  allow	  us	  to	  create	  a	  cyclic	  peptide	  library	  on	  resin	  that	  can	  be	  screened	  in	  cyclic	  forms,	  while	  able	  to	  revert	  back	  to	  its	  linear	  state	  for	  sequencing.	  We	  have	  begun	  to	  develop	  this	  cyclic	  peptide	  library	  on	  the	  TentaGel	  resin	  using	  the	  optimized	  photo	  labile	  linker	  chemistry	  for	  clean	  release	  of	  the	  peptides	  from	  the	  resin.	  Data	  presented	  herein	  supports	  the	  use	  of	  these	  UV	  sensitive	  linkers	  over	  chemically	  labile	  linkers,	  such	  as	  methionine,	  as	  a	  way	  to	  release	  desired	  peptides	  from	  the	  resin.	  Library	  members	  will	  include	  a	  terminal	  Dap(aoa)	  residue	  and	  an	  unnatural	  LB1	  moiety	  to	  serve	  as	  chemical	  handles	  for	  cyclization.	  Residues	  between	  the	  imino	  boronate	  forming	  residues	  will	  be	  incorporated	  via	  split-­‐pool	  synthesis	  to	  ensure	  diversity	  in	  peptide	  sequences.	  We	  have	  established	  preliminary	  assays	  to	  determine	  peptide	  sequences	  that	  bind	  lipids	  of	  biological	  relevance.	  Fluorescently	  labeled	  liposomes	  showed	  adequate	  fluorescence	  in	  microscopy	  studies	  to	  identify	  beads	  containing	  sequences	  of	  interest.	  Through	  these	  methods	  we	  will	  be	  able	  to	  select	  for	  sequences	  that	  tightly	  bind	  phosphatidylserine	  to	  label	  apoptotic	  cells.	  We	  can	  further	  modify	  the	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liposome	  composition	  to	  identify	  library	  members	  with	  selectivity	  for	  other	  lipids	  of	  interest	  or	  other	  membrane	  components.	  	  Optimization	  of	  the	  sequencing	  method	  had	  allowed	  us	  to	  detect	  a	  single	  bead’s	  worth	  of	  peptide.	  Further	  method	  optimization	  through	  parameter	  manipulation	  has	  provided	  access	  to	  valuable	  sequencing	  information	  through	  generation	  of	  y	  ion	  sequences	  in	  mass	  spectra.	  This	  ensures	  the	  success	  of	  our	  proposal	  to	  synthesize,	  screen,	  and	  sequence	  OBOC	  peptide	  libraries.	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Chapter	  4:	  Materials	  and	  Methods	  
I.	  Materials	  and	  General	  Methods	  	  Fmoc-­‐L-­‐Dap(boc-­‐aoa)-­‐OH	  and	  L-­‐cystine-­‐bis(tertbutyl	  ester)	  were	  purchased	  from	  Chem-­‐Impex	  International	  Inc.	  (Wood	  Dale,	  IL).	  	  All	  other	  Fmoc	  protected	  amino	  acids,	  Wang	  resin,	  Rink	  Amide	  MBHA	  resin	  and	  Fmoc-­‐Glu(Wang	  resin)-­‐OAllyl	  were	  purchased	  from	  Advanced	  Chemtech	  (Louisville,	  KY).	  O-­‐Benzotriazole-­‐N,N,N’N’-­‐tertramethyl-­‐uronium	  hexafluoro	  phosphate	  (HBTU),	  Benzotriazol-­‐1-­‐yl-­‐oxytripyrrolidinophosphonium	  hexafluorophosphate	  (PyBOP)	  were	  purchased	  from	  EMD	  Millipore	  (Billerica,	  MA).	  TentaGel	  resin	  was	  purchased	  from	  Anaspec	  (Freemont,	  CA).	  Boc	  Anyhydride,	  Trifluoromethanesulfonic	  anhydride,	  2,2,2-­‐trichloroacetimidate,	  nitrobenzene,	  dicyclohexylcarbodiiimide,	  dimethylaminopyridine	  were	  purchased	  from	  Sigma	  Aldrich	  (Milwaukee,	  WI).	  All	  other	  chemicals	  were	  purchased	  from	  Fisher	  Scientific	  (Pittsburgh,	  PA).	  1-­‐palmitoyl-­‐2-­‐oleoyl-­‐sn-­‐glycero-­‐phosphatidyl	  ethanolamine,	  1-­‐palmitoyl-­‐2-­‐oleoyl-­‐sn-­‐glycero-­‐3-­‐phosphocholine	  and	  1,2-­‐dioleoyl-­‐sn-­‐glycero-­‐3-­‐phospho-­‐L-­‐serine	  were	  purchased	  from	  Avanti	  Polar	  Lipids	  (Alabaster,	  AL).	  Peptide	  synthesis	  was	  conducted	  on	  the	  Tribute	  Peptide	  Synthesizer	  (Protein	  Technologies	  Tuscon,	  AZ).	  
1H,	  13C,	  11B	  NMR	  data	  were	  collected	  on	  the	  Varian	  500MHz	  spectrometer.	  LC-­‐MS	  data	  was	  collected	  on	  the	  Agilent	  1260	  series	  HPLC	  and	  Agilent	  6520	  LCTOF	  mass	  spectrometer	  (Agilent	  Technologies,	  Santa	  Clara,	  CA).	  Circular	  Dichroism	  was	  conducted	  on	  the	  Aviv	  420	  spectrometer	  (Biomedical	  Inc.,	  Lakewood,	  NJ).	  LUV’s	  were	  prepared	  using	  the	  Liposofast	  Mini	  Extrusion	  System	  (Avanti	  Polar	  Lipids,	  Alabaster,	  AL).	  Fluorescence	  microscopy	  was	  conducted	  on	  the	  Zeiss	  Axio	  Observer.	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A1	  (Thornwood,	  NY).	  UV	  experiments	  were	  conducted	  on	  the	  Thermo	  Scientific	  Nanodrop	  2000c	  	  (Waltham,	  MA).	  
II.	  Synthesis	  
	  
Scheme	  S1.	  Preparation	  of	  2	  
(1)	  Preparation	  of	  tert-­‐butyl	  S-­‐(((R)-­‐3-­‐(tert-­‐butoxy)-­‐2-­‐((tert-­‐
butoxycarbonyl)amino)-­‐3-­‐oxopropyl)thio)-­‐N-­‐(tert-­‐butoxycarbonyl)-­‐D-­‐
cysteinate	  L-­‐cystine	  bis(tert-­‐butyl	  ester)	  (5.0062g,	  118mmol)	  was	  dissolved	  in	  10%	  Sodium	  carbonate	  solution	  (50mL).	  Boc	  anhydride	  (6.5g,	  299mmol)	  was	  dissolved	  in	  tetrahydrofuran	  (50mL)	  and	  added	  to	  the	  reaction	  solution	  and	  allowed	  to	  stir	  at	  room	  temperature	  for	  24	  hours.	  The	  reaction	  solution	  was	  acidified	  to	  pH2	  with	  2N	  hydrochloric	  acid,	  extracted	  with	  ethyl	  acetate	  (3x	  100mL),	  washed	  once	  with	  brine	  and	  concentrated	  to	  give	  a	  white	  solid	  (7.2g,	  91%).	  
	  
Scheme	  S2.	  Preparation	  of	  2a	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oxopropyl)thio)-­‐N-­‐(tert-­‐butoxycarbonyl)-­‐D-­‐cysteinate	  (7.2g,	  13mmol)	  was	  dissolved	  in	  tetrahydrofuran	  (65mL)	  with	  tributylphosphine	  (7mL,	  26mmol)	  and	  water	  (2.7mL).	  After	  reacting	  overnight,	  the	  solution	  was	  concentrated	  and	  column	  purified	  on	  silica	  gel	  (hexanes/ethyl	  acetate	  10:0-­‐9:1)	  to	  yield	  white	  solid	  (7.1g,	  99%).	  
	  
Scheme	  S3.	  Preparation	  of	  4	  
(3)	  Preparation	  of	  1-­‐(4-­‐(allyloxy)-­‐2-­‐hydroxyphenyl)ethan-­‐1-­‐one	  Sodium	  iodoide	  (7.28g,	  49	  mmol)	  and	  allyl	  bromide	  (4.2mL,	  49	  mmol)	  were	  refluxed	  in	  acetone	  (75mL)	  for	  one	  hour.	  2,4-­‐dihydroxyacetophenone	  (5.00g,	  33	  mmol)	  was	  then	  added	  with	  potassium	  carbonate	  (4.14g,	  30	  mmol)	  in	  acetone	  (70mL)	  and	  allowed	  to	  react	  for	  22	  hours	  at	  65°C.	  Reaction	  was	  concentrated	  in	  vacuo	  and	  resuspended	  in	  water	  (50mL).	  Extracted	  with	  ethyl	  acetate	  (3x50mL)	  and	  washed	  once	  with	  brine	  (50mL).	  Purified	  with	  silica	  gel	  chromatography	  (hexanes/ethyl	  acetate	  4:1)	  to	  produce	  a	  white	  solid	  (4.4g,	  70%).	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(4)	  Preparation	  of	  2-­‐acetyl-­‐5-­‐(allyloxy)phenyl	  trifluoromethanesulfonate	  1-­‐(4-­‐(allyloxy)-­‐2-­‐hydroxyphenyl)ethan-­‐1-­‐one	  (4.55g,	  24	  mmol)	  was	  dissolved	  in	  dichloromethane	  (182mL)	  and	  chilled	  to	  -­‐78°C.	  Triethyl	  amine	  (13.4mL,	  96	  mmol)	  and	  trifluoromethanesulfonic	  anhydride	  (4.2mL,	  25	  )	  were	  added	  drop	  wise	  to	  the	  solution.	  After	  stirring	  for	  1	  hour,	  saturated	  sodium	  bicarbonate	  (90mL)	  was	  added.	  This	  was	  extracted	  with	  dichloromethane	  (2x	  90mL)	  and	  washed	  once	  with	  brine	  (80mL).	  Concentrated	  to	  give	  a	  black	  oil,	  which	  was	  then	  purified	  with	  sicila	  gel	  chromatography	  	  (hexanes/ethyl	  acetate	  8:2)	  to	  afford	  an	  off	  white	  solid	  (4.5g)	  
	  
Scheme	  S5.	  Preparation	  of	  6	  
(5)	  Preparation	  of	  tert-­‐butyl	  S-­‐(3-­‐(4-­‐acetyl-­‐3-­‐
(((trifluoromethyl)sulfonyl)oxy)phenoxy)propyl)-­‐N-­‐(tert-­‐butoxycarbonyl)-­‐L-­‐
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concentrated	  and	  purified	  by	  silica	  gel	  chromatography	  (hexanes/ethyl	  acetate	  85:15)	  to	  give	  an	  off	  white	  solid	  (2.652g,	  60%).	  
	  
Scheme	  S6.	  Preparation	  of	  7	  
(6)	  Preparation	  of	  tert-­‐butyl	  S-­‐(3-­‐(4-­‐acetyl-­‐3-­‐(4,4,5,5-­‐tetramethyl-­‐1,3,2-­‐
dioxaborolan-­‐2-­‐yl)phenoxy)propyl)-­‐N-­‐(tert-­‐butoxycarbonyl)-­‐L-­‐cysteinate	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Scheme	  S7.	  Preparation	  of	  AB1	  
(7)	  Preparation	  of	  N-­‐(((9H-­‐fluoren-­‐9-­‐yl)methoxy)carbonyl)-­‐S-­‐(3-­‐(4-­‐acetyl-­‐3-­‐
(4,4,5,5-­‐tetramethyl-­‐1,3,2-­‐dioxaborolan-­‐2-­‐yl)phenoxy)propyl)-­‐L-­‐cysteine	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Scheme	  S8.	  Preparation	  of	  8	  
(8)	  Preparation	  of	  tert-­‐butyl	  (3-­‐bromopropyl)carbamate	  
	  	  3-­‐bromopropanamine	  hydrobromide	  (1.0g,	  4.6mmol),	  boc	  anhydride	  (2.5g,	  11mmol)	  and	  sodium	  carbonate	  (488mg,	  4.6mmol)	  were	  dissolved	  in	  tetrahydrofuran	  (19mL)	  and	  water	  (19mL).	  After	  reacting	  24	  hours	  the	  reaction	  was	  acidified	  to	  pH	  2	  using	  2N	  hydrochloric	  acid	  and	  extracted	  with	  ethyl	  acetate	  (3x	  30mL).	  The	  organic	  layer	  was	  concentrated	  and	  purified	  on	  silica	  gel	  chromatography	  (hexanes/ethyl	  acetate	  7:3)	  to	  give	  the	  product	  as	  a	  white	  solid	  (889mg,	  82%).	  1H	  NMR	  (500MHz,	  chloroform-­‐d3)	  δ:	  4.62(broad,	  1H),	  3.40	  (t,	  2H),	  3.22	  (q,	  2H),	  2.01	  (m,	  2H),	  1.42	  (s,	  12H).	  
	  
Scheme	  S9.	  Preparation	  of	  9	  
(9)	  Preparation	  of	  tert-­‐butyl	  (3-­‐(4-­‐acetyl-­‐3-­‐hydroxyphenoxy)propyl)	  
carbamate	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tert-­‐butyl	  (3-­‐bromopropyl)carbamate	  (1.389g,	  6mmol),	  2,4-­‐dihydroxyacetophenone	  (713mg,	  5mmol),	  potassium	  carbonate	  (2.6g,	  19mmol)	  were	  dissolved	  in	  N,N-­‐dimethylformamide	  (9.4mL).	  After	  stirring	  at	  room	  temperature	  for	  4	  hours	  the	  reaction	  as	  acidified	  to	  pH	  2	  with	  2N	  hydrochloric	  acid	  and	  extracted	  with	  ethyl	  ether	  (5x	  10mL).	  The	  ether	  layer	  was	  washed	  once	  with	  water	  (10mL)	  and	  was	  then	  dried	  over	  anhydrous	  sodium	  sulfate.	  Purified	  on	  silica	  gel	  column	  (hexanes/ethyl	  acetate	  7:3-­‐5:5)	  to	  give	  the	  product	  as	  a	  white	  solid	  (441mg,	  24%).	  ESI+:	  MH+:	  	  calculated	  209.11,	  observed	  210.11.	  1H	  NMR	  (500MHz,	  chloroform-­‐d1)	  δ:	  7.8(d,	  1H),	  6.54	  (d,	  1H),	  6.41(s,	  1H),	  4.1	  (t,	  2H),	  3.25	  (q,	  2H),	  2.57	  (s,	  3H),	  2.15	  (m,	  2H),	  1.42	  (s,	  9H).	  
	  
Scheme	  S10.	  Preparation	  of	  10	  
(10)	  Preparation	  of	  2-­‐acetyl-­‐5-­‐(3-­‐((tert-­‐
butoxycarbonyl)amino)propoxy)phenyl	  trifluoromethanesulfonate	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sodium	  bicarbonate	  was	  added	  (8.4mL)	  and	  extracted	  with	  ethyl	  acetate	  (3x	  20mL).	  The	  organic	  layer	  was	  concentrated	  and	  purified	  on	  a	  silica	  gel	  column	  (hexanes/ethyl	  acetate	  8:2-­‐7:3)	  to	  yield	  the	  product	  as	  yellow	  oil	  (609mg,	  71%).	  ESI+:MH+:	  calculated	  427.09.	  1H	  NMR	  (500MHz,	  chloroform-­‐d1)	  δ:	  7.82	  (d,	  1H),	  6.95	  (d,	  1H),	  6.81	  (d,	  1H),	  4.7	  (broad,	  1H),	  4.1	  (t,	  2H),	  3.35	  (q,	  2H),	  2.6	  (s,	  3H),	  2.05	  (p,	  2H),	  1.42	  (s,	  9H).	  
	  
Scheme	  S11.	  Preparation	  of	  LB1	  
(11)	  Preparation	  of	  tert-­‐butyl	  (3-­‐(4-­‐acetyl-­‐3-­‐(4,4,5,5-­‐tetramethyl-­‐1,3,2-­‐
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concentrate	  was	  purified	  on	  silica	  gel	  chromatography	  (dichloromethane/ether	  10:0-­‐9:1)	  to	  afford	  an	  orange	  gel	  (162mg,	  28%).	  ESI+:MH+:	  calculated	  419.25,	  observed	  420.26.	  1H	  NMR	  (500MHz,	  chloroform-­‐d1)	  δ:7.9	  (d,	  1H),	  6.9	  (s,	  1H),	  6.85	  (d,	  1H),	  4.7	  (t,	  1H),	  4.08	  (t,	  2H),	  3.3	  (q,	  2H),	  2.55	  (s,	  3H),	  1.99	  (p,	  2H),	  1.42	  (s,	  21H).	  
	  
Scheme	  S12.	  Preparation	  of	  11	  
(12)	  Preparation	  of	  1-­‐(4-­‐(3-­‐aminopropoxy)-­‐2-­‐(4,4,5,5-­‐tetramethyl-­‐1,3,2-­‐
dioxaborolan-­‐2-­‐yl)phenyl)ethan-­‐1-­‐one	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and	  react	  for	  5	  hours.	  The	  reaction	  was	  then	  dried	  and	  purified	  by	  reversed	  phase	  preparatory	  HPLC	  (C-­‐18	  column,	  water/acetonitrile	  95:5-­‐5:95)	  to	  give	  the	  desired	  product	  as	  an	  oil	  (3.16mg).	  ESI+:MH+:	  calculated	  319.20,	  observed	  320.20.	  
	  
(13)	  Preparation	  of	  NBD-­‐POPE	  
	  1-­‐palmitoyl-­‐2-­‐oleoyl-­‐sn-­‐glycero-­‐3-­‐phosphoethanolamine	  (51.82mg,	  mmol)	  and	  4-­‐chloro-­‐7-­‐nitrobenzofuran	  (62mg,	  mmol)	  were	  dissolved	  in	  triethylamine	  (100uL)	  and	  chloroform	  (1mL)	  and	  allowed	  to	  react	  in	  the	  dark	  for	  6	  hours.	  The	  reaction	  was	  then	  diluted	  with	  chloroform	  and	  extracted	  with	  10%	  sodium	  carbonate	  solution.	  Purified	  on	  silica	  gel	  (dichloromethane/methanol	  95:5-­‐90:10)	  to	  give	  product	  (29mg,	  48%).	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Peptides	  were	  cleaved	  from	  the	  resin	  using	  Reagent	  K	  (80%	  TFA,	  5%	  water,	  2.5%	  ethanedithiol,	  5%	  thioanisole	  and	  7.5%	  phenol).	  
(15)	  Preparation	  of	  H2N-­‐ACVSWHGGCHPQGDICG-­‐OH	  The	  peptide	  was	  prepared	  using	  standard	  Fmoc/t-­‐butyl	  chemistry	  with	  5	  equivalents	  of	  commercially	  available	  amino	  acids	  and	  HBTU	  on	  the	  Fmoc-­‐Gly-­‐Wang	  resin	  solid	  support.	  Peptides	  were	  cleaved	  from	  resin	  using	  Reagent	  K	  (80%	  TFA,	  5%	  water,	  2.5%	  ethanedithiol,	  5%	  thioanisole	  and	  7.5%	  phenol)	  and	  purified	  by	  reversed	  phase	  preparatory	  HPLC	  (Waters	  prep	  LC,	  Jupiter	  10u,	  C4,	  300A	  column).	  
(16)	  Bicyclization	  of	  H2N-­‐ACVSWHGGCHPQGDICG-­‐OH	  Purified	  H2N-­‐ACVSWHGGCHPQGDICG-­‐OH	  was	  cyclized	  by	  incubating	  the	  peptide	  with	  1	  equivalent	  of	  tris(bromomethyl	  benzene)for	  1	  hour	  at	  30°C	  in	  60mM	  ammonium	  carbonate	  solution	  (500uL)	  and	  acetonitrile	  (500uL).	  
(17)	  Preparation	  of	  H2N-­‐AB1-­‐RG-­‐Dap(aoa)-­‐GQIHGFWDGGG-­‐OH	  and	  H2N-­‐AB1-­‐
RKGGQIHGFWDGGG-­‐OH	  H2N-­‐AB1-­‐RGKGQIHGFWDGGG-­‐OH	  and	  H2N-­‐AB1-­‐R-­‐
Dap(aoa)-­‐GGQIHGFWDGGG-­‐OH	  Peptides	  were	  synthesized	  on	  0.05mmol	  scale	  by	  standard	  Fmoc/tbu	  chemistry	  with	  5	  equivalents	  of	  commercially	  available	  amino	  acids	  and	  HBTU.	  AB1	  was	  coupled	  to	  the	  sequence	  using	  3	  equivalents	  of	  the	  unnatural	  amino	  acid	  and	  3	  equivalents	  of	  HBTU.	  The	  peptides	  were	  cleaved	  from	  resin	  using	  Reagent	  K	  (80%	  TFA,	  5%	  water,	  2.5%	  ethanedithiol,	  5%	  thioanisole	  and	  7.5%	  phenol)	  and	  purified	  by	  reversed	  phase	  preparatory	  HPLC	  (Waters	  prep	  LC,	  Jupiter	  10u,	  C4,	  300A	  column).	  
(18)	  Preparation	  of	  H2N-­‐AB1-­‐RG-­‐Dap(aoa)-­‐GGG-­‐Dap(aoa)-­‐W-­‐OH	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Peptides	  were	  synthesized	  on	  0.05mmol	  scale	  by	  standard	  Fmoc/tbu	  chemistry	  with	  5	  equivalents	  of	  commercially	  available	  amino	  acids	  and	  HBTU.	  AB1	  was	  coupled	  to	  the	  sequence	  using	  3	  equivalents	  of	  the	  unnatural	  amino	  acid	  and	  3	  equivalents	  of	  HBTU.	  The	  peptides	  were	  cleaved	  from	  resin	  using	  Reagent	  K	  (80%	  TFA,	  5%	  water,	  2.5%	  ethanedithiol,	  5%	  thioanisole	  and	  7.5%	  phenol)	  and	  purified	  by	  reversed	  phase	  preparatory	  HPLC	  (Waters	  prep	  LC,	  Jupiter	  10u,	  C4,	  300A	  column).	  
(19)	  Preparation	  of	  Magainin	  2	  Peptides	  were	  synthesized	  on	  0.1mmol	  scale	  by	  standard	  Fmoc/tbutyl	  chemistry	  with	  5	  equivalents	  of	  commercially	  available	  amino	  acids	  and	  HBTU	  on	  the	  Rink	  Amide	  MBHA	  resin	  solid	  support.	  Peptides	  were	  deprotected	  on	  resin	  then	  incubated	  overnight	  with	  triethylamine	  (40uL,	  mmol),	  DMF	  (2.96mL)	  and	  dansyl	  chloride	  (40mg,	  0.15mmol,	  3	  equivalent	  to	  resin)	  in	  the	  dark.	  The	  peptides	  were	  cleaved	  from	  resin	  using	  Reagent	  K	  (80%	  TFA,	  5%	  water,	  2.5%	  ethanedithiol,	  5%	  thioanisole	  and	  7.5%	  phenol)	  and	  purified	  by	  reversed	  phase	  preparatory	  HPLC	  (Waters	  prep	  LC,	  Jupiter	  10u,	  C4,	  300A	  column).	  
(20)	  Preparation	  of	  Magainin	  2	  Mutant	  with	  LB1	  Peptides	  were	  synthesized	  on	  0.05mmol	  scale	  by	  standard	  Fmoc/tbutyl	  chemistry	  with	  5	  equivalents	  of	  commercially	  available	  amino	  acids	  and	  HBTU	  on	  the	  Rink	  Amide	  MBHA	  resin	  solid	  support.	  The	  glutamate	  residue	  was	  deprotected	  with	  palladium	  tetrakis(triphenylphosphine)	  (60mg,	  mmol),	  phenyl	  silane	  (0.300mL,	  mmol)	  and	  dichloromethane	  (2mL)	  for	  1	  hour.	  The	  resin	  was	  then	  washed	  with	  dichloromethane	  (6x	  2mL)	  and	  deptrotected	  LB1	  (60mg,	  0.15mmol)	  was	  coupled	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using	  HBTU	  (55mg,	  0.15mmol)	  in	  0.4M	  NMM	  in	  DMF.	  	  Peptides	  were	  deprotected	  on	  resin	  then	  incubated	  overnight	  with	  triethylamine	  (40uL,	  mmol),	  DMF	  (2.96mL)	  and	  dansyl	  chloride	  (40mg,	  0.15mmol,	  3	  equivalent	  to	  resin)	  in	  the	  dark.	  The	  peptides	  were	  cleaved	  from	  resin	  using	  Reagent	  K	  (80%	  TFA,	  5%	  water,	  2.5%	  ethanedithiol,	  5%	  thioanisole	  and	  7.5%	  phenol)	  and	  purified	  by	  reversed	  phase	  preparatory	  HPLC	  (Waters	  prep	  LC,	  Jupiter	  10u,	  C4,	  300A	  column).	  
III.	  Measurements	  
(1)	  Model	  iminoboronate	  formation	  studies	  50uM	  2-­‐acetylphenylboronic	  acid	  was	  prepared	  in	  1x	  PBS	  buffer	  at	  pH	  7.	  6-­‐aminooxyhexanoic	  acid	  or	  lysine	  each	  prepared	  in	  1x	  PBS	  buffer	  was	  titrated	  into	  the	  2-­‐APBA	  stock	  and	  the	  UV	  spectra	  was	  recorded.	  	  
(2)	  Peptide	  iminoboronate	  formation	  studies	  500uM	  peptide	  was	  prepared	  in	  1x	  PBS	  buffer	  and	  the	  UV	  absorbance	  was	  recorded.	  
(3)	  Small	  molecule	  competition	  assay	  with	  model	  peptides	  H2N-­‐AB1-­‐GG-­‐Dap(aoa)W-­‐OH	  was	  prepared	  as	  a	  50uM	  stock	  solution	  and	  varying	  concentrations	  of	  6-­‐aminooxyhexanoic	  acid	  or	  4-­‐hydrazinobenzoic	  acid	  were	  tritrated	  into	  samples.	  The	  samples	  were	  then	  analyzed	  by	  LC-­‐MS	  and	  percent	  linear	  and	  cyclic	  peptides	  were	  calculated	  by	  integrating	  the	  UV	  trace	  at	  254nm.	  
(4)	  Circular	  dichroism	  of	  Magainin	  2	  and	  Magainin	  2	  LB1	  mutant	  Peptides	  were	  prepared	  in	  50uM	  concentration	  1x	  PBS	  buffer	  in	  the	  presence	  of	  SDS	  micelles.	  For	  each	  spectrum	  two	  scans	  were	  obtained	  and	  averaged	  and	  plotted.	  
(5)	  Circular	  dichroisim	  with	  HBA	  and	  Magainin	  2	  LB1	  mutant	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50uM	  mutant	  peptide	  in	  the	  presence	  of	  50mM	  SDS	  micelles	  in	  1x	  PBS	  buffer	  and	  4-­‐hydrazinobenzoic	  acid	  prepared	  in	  1x	  PBS	  buffer	  was	  titrated	  in	  prior	  to	  scans.	  Wavelength	  scans	  were	  obtained	  in	  duplicate	  and	  the	  trials	  were	  averaged	  and	  plotted.	  
(6)	  Cyanogen	  bromide	  cleavage	  of	  peptides	  from	  TentaGel	  resin	  peptides	  on	  the	  TentaGel	  resin	  were	  placed	  in	  40mg/mL	  cyanogen	  bromide	  in	  70%	  trifluoroacetic	  acid	  in	  water	  solution	  in	  the	  dark	  and	  were	  incubated	  at	  room	  temperature	  overnight.	  	  
(7)	  Photo	  cleavage	  Resin	  was	  placed	  in	  clear	  glass	  vials	  with	  methanol	  and	  placed	  under	  365nm	  UV	  light.	  Optimal	  results	  came	  from	  light	  sources	  with	  160W	  power	  for	  1	  hour.	  
(8)	  Partial	  Edman	  degradation	  20mg	  Resin	  was	  swelled	  for	  1	  hour	  in	  500uL	  1:1	  pyridine/water	  and	  filtered.	  Equal	  volumes	  of	  1:1	  pyridine/water	  (250uL)	  and	  20:780	  phenylisocyanate/pyridine	  (250uL)	  were	  added	  to	  the	  resin	  and	  were	  allowed	  to	  incubate	  for	  30	  minutes	  in	  the	  dark.	  Resin	  was	  then	  filtered	  and	  incubated	  with	  500uL	  of	  trifluoroacetic	  acid	  for	  10	  minutes	  in	  the	  dark.	  Resin	  was	  then	  filtered,	  washed	  thoroughly	  with	  dichloromethane	  (3x),	  and	  methanol	  (3x).	  Process	  was	  repeated	  for	  subsequent	  degradation.	  
(9)	  Optimized	  LC-­‐MS	  methods	  for	  peptide	  sequencing	  Default	  settings	  for	  the	  Agilent	  6520	  were	  manipulated	  to	  an	  optimal	  capillary	  voltage	  of	  4500V,	  skimmer	  voltage	  of	  115V,	  drying	  gas	  temperature	  of	  350°C	  and	  flow	  rate	  of	  8L/minute.	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(10)	  Liposome	  preparation	  	  POPC,	  POPS	  and	  NBD	  labeled	  POPE	  were	  placed	  in	  a	  vial	  in	  chloroform	  in	  desired	  ratio	  and	  left	  on	  vacuum	  to	  remove	  all	  chloroform	  for	  2	  days.	  Resuspended	  lipids	  in	  1x	  PBS	  buffer	  at	  pH	  7.4.	  Liposomes	  were	  subjected	  to	  20	  freeze	  thaw	  cycles	  and	  extruded	  through	  a	  100nm	  filter	  20	  times.	  
(11)	  Library	  preparation	  Linker	  from	  the	  TentaGel	  resin	  was	  synthesized	  using	  standard	  Fmoc	  solid	  phase	  peptide	  synthesis	  with	  dichloromethane	  as	  the	  primary	  solvent	  in	  place	  of	  DMF.	  6	  rounds	  of	  split-­‐pool	  synthesis	  were	  then	  performed	  on	  the	  linker	  using	  commercially	  available	  Fmoc-­‐Arg	  (pbf)-­‐OH,	  Fmoc-­‐Asp(otbu)-­‐OH,	  Fmoc-­‐Gln(trt)-­‐OH,	  Fmoc-­‐His(trt)-­‐OH,	  Fmoc-­‐Ile-­‐OH	  and	  Fmoc-­‐Gly-­‐OH	  with	  HBTU.	  After	  6	  rounds	  of	  split	  and	  pool	  synthesis	  Fmoc-­‐Cys(trt)-­‐OH	  was	  coupled	  to	  the	  resin.	  The	  resin	  was	  then	  deprotected	  in	  bulk	  in	  the	  dark	  with	  reagent	  K	  for	  1	  hour.	  Peptides	  were	  oxidized	  in	  water	  with	  air	  bubbling	  overnight.	  
(12)	  Fluorescence	  imaging	  studies	  TentaGel	  resin	  bearing	  the	  oxidized	  peptide	  library	  was	  incubated	  for	  10	  minutes	  in	  the	  dark	  with	  1mM	  liposome	  stock	  of	  either	  99.9%	  POPC	  0.1%	  NBD-­‐POPE	  vesicles	  or	  80%	  POPC	  20%	  POPS	  with	  0.1%	  NBD-­‐POPE	  vesicles.	  Beads	  were	  washed	  with	  1x	  PBS	  buffer	  and	  resuspended	  in	  1xPBS	  buffer	  for	  imaging	  under	  bright	  field	  and	  PITC	  channel	  for	  fluorescence.	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